Discontinuation of Anti-Estrogen Therapy and Body Aches
The evidence clearly demonstrates that body aches are associated with taking anti-estrogen therapy (particularly aromatase inhibitors), not with discontinuing it—in fact, discontinuation typically leads to symptom resolution. 1, 2, 1
Understanding the Relationship Between Anti-Estrogen Therapy and Musculoskeletal Symptoms
During Active Treatment
Up to 50% of postmenopausal women receiving aromatase inhibitor medications (anastrozole, letrozole, exemestane) report arthralgias (joint pain) and myalgias (muscle pain) severe enough that 20% discontinue treatment due to these symptoms. 1, 2, 1
- These aromatase inhibitor-associated musculoskeletal symptoms are often not responsive to NSAIDs or acetaminophen 1, 2
- The symptoms typically manifest as severe early morning stiffness, hand/wrist pain, and impaired ability to perform daily activities 3
- MRI studies show characteristic tenosynovial changes including enhancement and thickening of tendon sheaths in affected patients 3
Upon Discontinuation
When patients discontinue anti-estrogen therapy due to intolerable musculoskeletal symptoms, the symptoms typically improve or resolve during the washout period. 4, 5
- In a prospective study, patients who discontinued their initial AI due to adverse effects had a 2-8 week washout period before potentially switching to another AI 4
- After discontinuing anastrozole due to musculoskeletal symptoms and waiting 1 month, 71.5% of patients were able to tolerate switching to letrozole 5
- This demonstrates that the body aches are caused by the presence of the medication, not its absence 4, 5
Clinical Implications
For Patients Currently on Therapy
Approximately 40% of patients who discontinue one AI may tolerate a different aromatase inhibitor or formulation; the remainder generally tolerate tamoxifen. 1, 2, 1
- Switching between AIs (anastrozole, letrozole, exemestane) can allow continuation of hormonal therapy in many patients 4, 5
- Poor adherence to therapy increases the risk of breast cancer recurrence, making symptom management critical for mortality outcomes 1, 2
Evidence-Based Management During Active Treatment
Only acupuncture and exercise have demonstrated statistically significant improvement in aromatase inhibitor-associated symptoms. 1, 2, 1
- Intensive exercise regimens result in a 20% decrease in AI-associated pain 1, 2, 1
- A mixed-modality regimen of 150 minutes weekly aerobic exercise plus two sessions of resistance training (at least six exercises, 8-12 repetitions, three sets each) is recommended 6
- Supplementary yoga or tai chi twice weekly may provide additional benefit for physical functionality and mental health 6
Common Pitfall to Avoid
Do not attribute new-onset body aches occurring after stopping anti-estrogen therapy to the discontinuation itself. If a patient develops musculoskeletal symptoms after stopping these medications, alternative etiologies should be investigated, as the pharmacologic mechanism suggests symptom improvement, not worsening, with cessation. 4, 5, 3
The FDA labeling for exemestane specifically lists arthralgia as occurring in 15% of patients during active treatment, with musculoskeletal events being more common than with tamoxifen. 7 Similarly, tamoxifen labeling documents that musculoskeletal events occur in 36% of anastrozole-treated patients versus 29% with tamoxifen during active therapy. 8